Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by DigitalSpurson Apr 15, 2020 11:59pm
349 Views
Post# 30914709

IV version of the Drug (KEY POINTS TO TAKE AWAY)

IV version of the Drug (KEY POINTS TO TAKE AWAY)https://ca.proactiveinvestors.com/companies/news/917329/algernon-pharmaceuticals-gets-fda-thumbs-up-on-new-intravenous-version-of-ifenprodil-917329.html


A lot of people probably haven't even noticed the above article and compared it to the below:

https://www.globenewswire.com/news-release/2020/04/13/2015035/0/en/Algernon-Receives-Positive-Feedback-from-U-S-FDA-for-Ifenprodil-COVID-19-Human-Trial-Appoints-U-S-Ambassador-Rtd-Howard-Gutman-to-Advisory-Board.html


The first link is April 15, 2020 (TODAY) - second link is April 13 - two different news stories.




KEY POINTS to take away and why I believe, as the stock market is forward looking, we will see a HUGE jump in price come this time next week:

1. Canada is in the works

2. South Korea is in the works

3. Since March 9, there has been 15 (YES, 15!!) news releases from the company - this thing is moving faster than a McClaren-Mercedes at the Grand Prix!!!!

4. Along with 3 above, if not already noted, expect news to come down like crazy!!!

5. Finally, with the above, the stock market won't wait until the 29th day of the trial for a drug that has already been FDA approved (and now only synthesized into an IV) to know it's safe and move onto human testing for the stock price to move - we will see a VERY BULLISH run here soon and I know many have said this will run like some other stocks - almost EXACTLY like the run Sona Nanotech made


Buckle UP!!!!! Looking great and I'm happy I' m locked and loaded with my shares. Won't even consider selling for anything under $3. 
Bullboard Posts